Cutaneous B-cell Lymphoma Treatment Market Size, Share & Industry Analysis, By Type (Radiation Therapy, Chemotherapy, Monoclonal Antibodies, Others (Corticosteroids, Interferons, etc.)), By End-user (Hospitals, Speciality Clinics, Others) and Regional Forecast, 2024-2032

Cutaneous B-cell lymphoma is a rare form of cancer that occurs in the white blood cells and attacks the skin. The cutaneous B-cell lymphoma is classified into primary cutaneous follicle center lymphoma, primary cutaneous marginal zone B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma, and intravascular diffuse large B-cell lymphoma.

B-cell lymphomas account for 85 percent of all non-Hodgkin lymphoma (NHL) cases in the United States. The disease affects men and women equally, and any age group can be affected. Diagnosis of cutaneous b-cell lymphoma includes various tests including imaging tests, bone-marrow biopsies, blood test, and skin biopsy test, among others.

Increasing prevalence of the non-Hodgkin lymphoma (NHL) cases is one of the major factors propelling the cutaneous B-cell lymphoma treatment market growth. According to the an article published by NCBI in 2015, primary cutaneous lymphomas (PCL) are the most recurrent extra-nodal lymphomas, with incidence of approximately 10 cases per million population per year, out of which 20-30% are primary cutaneous B-cell lymphomas (PCBCL).

The increasing prevalence of primary cutaneous B-cell lymphomas is one of the major factor presenting a large patient pool requiring treatment, subsequently driving the growth of the global market. Increasing investment in research and development for the development of the novel products in order to cure cutaneous B-cell lymphoma is one of the major factor anticipated to propel the cutaneous B-cell lymphoma treatment market growth during the forecast period of 2019-2026.

In October 2017, U.S. Food and Drug Administration approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. The new product approvals for the treatment of B-cell lymphoma in developed and developing countries is one of the major factor likely to drive the growth of the global cutaneous B-cell lymphoma market during forecast period.

On the flip side, the lack of approved drugs for the treatment of cutaneous b-cell lymphoma, and high cost of the treatment are some of the factors restraining the growth of the global cutaneous B-cell lymphoma market.

Key Players Covered

The major companies covered in the global cutaneous B-cell lymphoma treatment market report include Kite Pharma, Genentech, Inc., Novartis AG, Epizyme, Inc., NanoString Technologies, Inc., Amgen Inc., Johnson & Johnson Services, Inc. and other players.

Segmentation

As per the current cutaneous B-cell lymphoma treatment market trends, chemotherapy among the type accounted for the largest market share in the global cutaneous B-cell lymphoma treatment market in 2018.

Key Insights

• Prevalence of Lymphoma, Key Countries/ Regions, 2018


• New Product Launches, by Key Market Players


• Pipeline Analysis


• Key mergers and acquisitions

Regional Analysis

The global cutaneous B-cell lymphoma treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global cutaneous B-cell lymphoma treatment market in 2018 followed by Europe. Asia Pacific is anticipated to grow at significant CAGR during the forecast period due increased investment by key market players in the research and development of the treatment for the cutaneous B-cell lymphoma. Latin America and Middle East and Africa account for relatively lower share and are projected to grow at a comparatively lower CAGR during the forecast period.

Cutaneous B-cell Lymphoma Treatment Industry Developments

• In June 2019, Kite Pharma reported findings from two new analyses from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.


• In June 2019, Genentech, Inc. received Food and Drug Administration approval to polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.), a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).